Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
PRPraxis Precision Medicines, Inc. logo

Praxis Precision Medicines, Inc. (PRAX)

NASDAQ Global Select · Currency in USD
$252.96 ▼ -5.96 (-2.30%)
At close: Oct 23, 4:00 PM ET. Market closed.
$248.03 ▼ -4.93 (-1.95%)
After hours: Oct 23, 7:37 PM ET

Summary

Previous Close
$258.92
Open
$256.89
Day's Range
$250.88 – $257.40
52 Week Range
$154.45 – $392.70
Volume
371,622
Avg. Volume
476,880
Market Cap
$7.06B
Beta (5Y Monthly)
2.81
PE Ratio (TTM)
--
EPS (TTM)
-$11.64
Earnings Date
Nov 9, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$611.69

Profile: Praxis Precision Medicines, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
168
CEO
Marcio Silva De'Souza

Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor.

Earnings

Next report: Mon, Nov 9, 2026
EPS estimate -$3.54 · Revenue est. $130.77K
DateEst.Actual
Aug 6, 2026-$3.67-$2.87Beat
May 7, 2026-$3.58-$3.20Beat
Feb 19, 2026-$3.13-$3.50Miss
Nov 5, 2025-$3.45-$3.36Beat
Aug 4, 2025-$3.40-$3.31Beat
May 2, 2025-$3.20-$3.29Miss

Analyst view

Consensus price target
$611.69 ▲ +141.8%
Range $162.00 – $1,201.00
Rating: Buy
Buy 78% · Hold 17% · Sell 6%

Get free alerts on PRAX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.